Is danuglipron a peptide?

No. Danuglipron is a synthetic small molecule (non-peptide) GLP-1 receptor agonist. It is fundamentally different from peptide GLP-1 agonists like semaglutide or liraglutide. It is included on PeptideAtlas for comparison purposes because it targets the same receptor.

Why did Pfizer stop developing twice-daily danuglipron?

The twice-daily formulation had unacceptably high GI side effect rates, with up to 50% of patients discontinuing in the highest dose group. Pfizer pivoted to a once-daily modified-release formulation designed to smooth pharmacokinetics and improve tolerability.

How does danuglipron compare to oral semaglutide?

Oral semaglutide (Rybelsus) is a peptide that requires an absorption enhancer (SNAC) and must be taken on an empty stomach 30 minutes before food. Danuglipron is a small molecule that does not require these conditions, potentially offering more convenient dosing. However, oral semaglutide is already FDA-approved with extensive clinical data, while danuglipron is still investigational.

What is the recommended dose range for Danuglipron?

The research dose range is 40–120 mg oral (Phase 2 tested up to 120 mg BID; MR formulation doses TBD), administered via Oral, Once daily (modified-release) or twice daily (immediate-release).

peptide dosing

Danuglipron Dosing & Reconstitution Guide

Complete dosing reference for Danuglipron (Metabolic / Oral GLP-1 Agonist (Small Molecule)). Covers reconstitution, dose range, titration schedule, pharmacokinetics, and storage protocols for research use.

Dosing Protocol

Route: Oral Frequency: Once daily (modified-release) or twice daily (immediate-release) Dose Range: 40–120 mg oral (Phase 2 tested up to 120 mg BID; MR formulation doses TBD)

Safety & Contraindications

Safety: Common: nausea (up to 42%), vomiting, diarrhea — significantly higher rates than injectable GLP-1 agonists High discontinuation rates in Phase II: up to 50% of patients in the highest dose group discontinued, primarily due to GI adverse events GI tolerability was the primary reason Pfizer discontinued the twice-daily formulation and pivoted to modified-release

Contraindications: Personal or family history of medullary thyroid carcinoma (GLP-1 class caution, though small molecules may have different risk); Multiple endocrine neoplasia syndrome type 2 (MEN2); Severe hepatic impairment (hepatically metabolized small molecule)

Peptide Tools

Reconstitution CalculatorCalculate concentration and syringe units for any peptide vial with visual syringe guide.

Dosage & Cycle PlannerPlan a multi-week peptide cycle. Calculate total supply needed and vial counts.

Bacteriostatic Water CalculatorCalculate how many vials of bacteriostatic water you need for your peptide stack.

Cost-Per-Milligram CalculatorCompare vendors side-by-side. Find the best value per milligram and per dose.

Frequently Asked Questions

Related Resources

Browse All Research Peptides

Explore More

Danuglipron Dosing Guide Peptides for Weight Management Peptides for Metabolic Health

Research Use Only. The information on this page is compiled from published research literature and is provided for educational purposes only. It does not constitute medical advice. All compounds referenced are intended for in vitro research use by qualified laboratories and institutions.